2020 Fiscal Year Final Research Report
The role of matricellular proteins in intraocular fibrovascular proliferation induced by anti-VEGF therapy
| Project/Area Number |
19K18899
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56060:Ophthalmology-related
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2021-03-31
|
| Keywords | マトリセルラー蛋白 / 線維血管増殖 / 抗VEGF療法 / ペリオスチン / テネイシンC |
|---|
| Outline of Final Research Achievements |
To determine whether matricellular proteins are involved in intraocular fibrovascular proliferation, the protein concentration of matricellular proteins in aqueous humor and vitreous was investigated before and after anti-VEGF therapy. We found that the level of periostin protein in the diabetic retinopathy group was significantly higher than that in the control group. Although the level of periostin protein increased after anti-VEGF therapy in case with increased fibrovascular proliferation, the level of VEGF protein was not increased. The effect of periostin on fibrovascular proliferaion was stronger than that of tenascin C.
|
| Free Research Field |
線維血管増殖
|
| Academic Significance and Societal Importance of the Research Achievements |
抗VEGF療法誘導性の眼内線維増殖の発症進展にペリオスチンを主としたマトリセルラー蛋白が関与していると考えられた。今回得られた成果から、ペリオスチンを標的とした治療が、抗VEGF療法誘導性の眼内線維増殖に対する新規治療となり得ると考えられた。マトリセルラー蛋白は、正常網膜での発現レベルは低く、線維血管増殖組織に特徴的に発現していると考えられるため、 マトリセルラー蛋白を標的とした新規治療を創製できれば、正常網膜にほとんど障害を与えることなく、線維血管増殖組織のみを抑制する病態特異的な治療法となることが期待される。
|
